Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial
American College of Cardiology/American Heart Association Task Force on Practice, S
Busy Professionals and Frequent Travelers Many professionals work long hours, travel frequently, or have irregular schedules
Individuals with a history of cancer or concerning family history may wish to avoid compounds that increase IGF-1 and potentially support cell proliferation
Rare but Serious Reactions: Seek immediate medical attention for signs of a severe allergic reaction (anaphylaxis), such as hives, difficulty breathing, or swelling of the face and throat
Important Safety Information Contraindications: Active cancer or malignancy (use only with medical supervision) Pregnancy or breastfeeding (insufficient safety data in these populations) Known allergy to peptide compounds Severe uncontrolled medical conditions without physician oversight Monitoring recommendations: While intensive monitoring is not required as with growth hormone, baseline and periodic assessment of body composition, basic metabolic panel, and general health markers ensures optimal results and safety
